Back to top

Spyre Therapeutics initiated with a Buy at Deutsche Bank

Deutsche Bank initiated coverage of Spyre Therapeutics (SYRE) with a Buy rating and $43 price target The company’s goal is to create improved biolo...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Spyre Therapeutics, Inc. (SYRE)